Abstract:Abstract Purpose Our aim was to characterize the newly established new drug conditional approval process in China and discuss the challenges and opportunities with respect to new drug research and development and registration. Methods We examined the new approval program through literature review, law analysis, and data analysis. Data were derived from published materials, such as journal articles, government publications, press releases, and news articles, along with statistical data from INSIGHT-China Pharma Databases, the China Food and Drug Administration website, the Center for Drug Evaluation website, the US Food and Drug Administration website, and search results published by Google. Findings Currently, there is a large backlog of New Drug Applications in China, mainly because of the prolonged review time at the China Food and Drug Administration, resulting in a lag in drug approvals. In 2015, the Chinese government implemented the drug review and registration system reform and tackled this issue through various approaches, such as setting up a drug review fee system, adjusting the drug registration classification, and establishing innovative review pathways, including the conditional approval process. Implications In Europe and the United States, programs comparable to the conditional approval program in China have been well developed. The conditional approval program recently established in China is an expedited new drug approval process that is expected to affect new drug development at home and abroad and profoundly influence the public health and the pharmaceutical industry in China. Like any program in its initial stage, the conditional approval program is facing several challenges, including setting up a robust system, formatting new drug clinical research requirements, and improving the regulatory agency’s function for drug review and approval. The program is expected to evolve and improve as part of the government mandate of the drug registration system reform.

Comparisons on New Drug Technical Review Between SFDA and FDA

Comparative Analysis Between SFDA and FDA of Drug Administration Information Disclosure System

Comparison of clinical review and regulation for biologics and chemical drugs of FDA:a case study of type 2 diabetes mellitus

Evaluation on New Drug Registration System in America and Its Illumination for China

Discussion on the similarities and differences of statistical guidance on reporting results from evaluating diagnostic reagent tests of SFDA and FDA

New Problems in FDA Problems in Drug Registration

Comparison of Marketing Authorization System for Drug Wholesale Enterprises between China and America

Overview of Drug Evaluation System in China

The New Drug Conditional Approval Process in China: Challenges and Opportunities

Comparison of Drug Control Between China and USA

Discussion on the Major Changes of Drug Administration Acceptance Review and Approval System

On the Amendments of China’s Provisions for Drug Registration

Performance appraisal system of new drug review in Japan and its reference to China

Research on priority review of new drugs in China

Opinions and suggestions of bioequivalent studies on modified new drugs

Regulatory watch: Innovative drug availability in China.

Recent Advances in Drug Development and Regulatory Science in China

Evolution of FDA's NDA/BLA review process under PDUFA

The Comparative Study on Supervision and Incentive Policies of Sino-US During the Innovative Drug R&D

Comparative Analysis of Drug Management Law in China with Related Laws and Regulations in America about the Definition of Counterfeit and Inferior Drugs and Its Enlightenment

Research on the link between expedited review and drug reevaluation from the perspective of innovation incentive based on American experience